SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
RESPONSE GENETICS INC
(NASDAQ:RGDX Last Sale: 2.81 +.1)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NASDAQ: (RGDX : $2.81)
$51 million Market Cap at Market Close, July 29, 2010
Biomedics SubIndustry down < .38%> / Health Industry down < .37> Today
1640 Marengo Street Research Report Earnings Snapshot - Last 03/09/09
Los Angeles, CA 90033 Annual Reports
Phone: 323-224-3900

Kathleen Danenberg, CEO/Pres., David D. O'Toole, CFO
Focus on genetic analysis of tumor tissues, as diagnostic tests for cancer recurrence or chemotherapy response are based on the genetic analysis of RNA extracted from tumor tissue. Has a services agreement with SmithKline Beecham Corporation. Incorporated in Delaware in September 1999 as Bio Type, Inc. Name change in August 2000. IPO at $7 June 4, 2007. Raised $21 million, selling 3 million shares, 30% of the outstanding. Lead Manager: Maxim Group LLC.
Historical Charts    Technical Analysis

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common RGDX $2.81 $2.71 .1 3.7 $2.67 $3.24 13,531 $1.103 $3.24 18,303
Capitalization
Earnings Summary
Annual EarningsQuarterly Earnings
 
 
Earnings
Growth
Prior
Surprise
Estimate
Last
2008
$( 0.84)e
 
 
 
$( 0.84)e
Last
Q3-2008
$( 0.21)a
-133%
vs. $( 0.09)a
-11%
$( 0.19)e
Current
Q4-2008
$( 0.25)e
 
 
 
$( 0.25)e
Common Stock $51,431

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2010 Stock Smart with all rights reserved
Quotes are delayed 15 minutes or more for Nasdaq, 20 minutes or more for NYSE/AMEX. Provided by TTI